Sugi Predict

Sugi Predict / Compounds / SCHEMBL16637040

SCHEMBL16637040

SCHEMBL16637040

COc1cccc(F)c1-c1c(Cl)cc2c(N3CCN(C(=O)OC(C)(C)C)CC3)ncnc2c1F

nearest known ligand 0.59

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ KRAS P01116 7/20 0.59
▸ EGFR P00533 1/20 0.59
▸ HMOX2 P30519 1/20 0.59
▸ CRYZ Q08257 1/20 0.59
▸ VAT1 Q99536 1/20 0.59
▸ RTN4 Q9NQC3 1/20 0.59
▸ KIT P10721 2/20 0.47
▸ CNR1 P21554 1/20 0.43
▸ CNR2 P34972 1/20 0.43
▸ PDGFRB P09619 7/20 0.43
▸ CXCR2 P25025 1/20 0.42
▸ TNF P01375 1/20 0.41
▸ LITAF Q99732 1/20 0.41
▸ PDGFRA P16234 1/20 0.41
▸ ALK Q9UM73 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23564878 0.93 KRAS (0.52) KRASEGFRHMOX2CRYZVAT1
SCHEMBL19681380 0.89 KRAS (0.63) KRASEGFRHMOX2CRYZVAT1
SCHEMBL18128388 0.89 KRAS (0.45) KRASEGFRHMOX2CRYZVAT1
SCHEMBL31657979 0.89 KRAS (0.45) KRASEGFRHMOX2CRYZVAT1
SCHEMBL18133934 0.89 KRAS (0.48) KRASEGFRHMOX2CRYZVAT1
SCHEMBL31658141 0.89 KRAS (0.48) KRASEGFRHMOX2CRYZVAT1
SCHEMBL18964388 0.88 KRAS (0.48) KRASEGFRHMOX2CRYZVAT1
SCHEMBL18964392 0.88 KRAS (0.48) KRASEGFRHMOX2CRYZVAT1
SCHEMBL31657946 0.88 KRAS (0.48) KRASEGFRHMOX2CRYZVAT1
SCHEMBL18964042 0.88 KRAS (0.47) KRASEGFRHMOX2CRYZVAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630547-B2 RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications BIOTHERYX, INC. (US) 2026-05-19 — — US disclosed
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2025-02-25 — — US disclosed
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-10-24 — — US disclosed
US-20240043441-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2024-02-08 — — US disclosed
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2024-01-23 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
US-20230303586-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-09-28 — — US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 — — US disclosed
US-20230212183-A9 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2023-07-06 — — US disclosed
US-20230002371-A1 RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS BIOTHERYX INC (US) 2023-01-05 — — US disclosed
US-20170190672-A1 METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES ARAXES PHARMA LLC 2017-07-06 — — US disclosed
WO-2017100546-A1 METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES ARAXES PHARMA LLC (US) 2017-06-15 — — WO disclosed
WO-2017100546-A1 METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES ARAXES PHARMA LLC (US) 2017-06-15 — — WO disclosed
EP-3055290-A1 INHIBITORS OF KRAS G12C Araxes Pharma LLC (US) 2016-08-17 — — EP disclosed
WO-2016049568-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF RAS ARAXES PHARMA LLC (US) 2016-03-31 — — WO disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
US-20150239900-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC 2015-08-27 — — US disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed
WO-2015054572-A1 INHIBITORS OF KRAS G12C ARAXES PHARMA LLC (US) 2015-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630547-B2 RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications KRAS, RSU1, NRAS KRAS 1/4885EGFR 479/4885HMOX2 2652/4885
US-12234244-B2 Substituted piperazines as inhibitors of KRAS G12C KRAS, NRAS, HRAS KRAS 1/4885EGFR 235/4885HMOX2 4490/4885
US-20170190672-A1 METHODS FOR PREPARATION OF QUINAZOLINE DERIVATIVES TTBK2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TTBK1 KRAS 1369/4885EGFR 4238/4885HMOX2 4345/4885
US-11878985-B2 Substituted quinazolines as inhibitors of KRAS G12C KRAS, NRAS, HRAS KRAS 1/4885EGFR 262/4885HMOX2 4165/4885
US-20240352028-A1 SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS KRAS 1/4885EGFR 262/4885HMOX2 4165/4885
US-20150239900-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS KRAS 1/4885EGFR 180/4885HMOX2 4456/4885
US-20230212183-A9 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS KRAS 1/4885EGFR 180/4885HMOX2 4456/4885
US-20230002371-A1 RAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS KRAS, RSU1, RAB1A KRAS 1/4885EGFR 246/4885HMOX2 2878/4885
US-20240043441-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS KRAS 1/4885EGFR 180/4885HMOX2 4456/4885
US-20230303586-A1 INHIBITORS OF KRAS G12C KRAS, NRAS, HRAS KRAS 1/4885EGFR 180/4885HMOX2 4456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.